Issue 1/2023
Stefanov, S., Ganeva, M., Dasheva-Dimitrova, A., Hristova, D.,
Telcharova-Mihailovska, A., Kaleva, V., Temelkova, K., Vasilev, T.
Clinic of rheumatology, cardiology and hematology, SBALDB, MU – Sofia
Scientific statistics during the COVID-19 pandemic registered multisystem inflammatory syndrome in children (Multisystem inflammatory syndrome in children, MIS-C). MIS-C is a disease that manifests after COVID-19 infection and mainly affects school-aged children. It is important to note that the syndrome is not common, but it can be serious. It includes classic signs of inflammation, multiorgan dysfunction affecting the skin, mucous membranes, heart, gastrointestinal tract (GIT), and nervous system, as well as laboratory evidence of inflammation. Fever is the leading symptom In the clinic of rheumatology, 14 boys and 15 girls aged from 1 to 17 years were treated, i.e. the average age was 7.44 years. Our practical experience with children suffering from multiinflammatory syndrome is analogous to the scientific publications in the international literature on the subject. Treatment is aimed at affecting immune dysregulation and inflammation. In this regard, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressants, biological agents, as well as a natural alternative with a proven effect – vitamin D3, zinc, selenium, antioxidants, vitamins, etc. are applied. A proven natural alternative that regulates immunity and suppresses inflammation is the product Imuflam (Borola Ltd).
Address for correspondence:
S. Stefanov
UMBALDB „Prof. Dr. Ivan Mitev“, Clinic of Rheumatology
11 „Akad. Ivan Evstratiev Geshov“ Blvd.,
1612, Sofia
e-mail: snsnedev@abv.bg